Tocilizumab · intravenous infusion
Misc., Injections & Implants
OFF-LABELNot in the FDA label for this product
Non-infectious intermediate, posterior or panuveitis
4 mg/kg or 8 mg/kg by intravenous infusion every 4 weeks
RCT · n=37 · no control arm
STOP-Uveitis randomized 37 patients to 4 mg/kg or 8 mg/kg intravenous tocilizumab every 4 weeks to month 6. Its primary endpoint was safety, and repeated infusions were well tolerated; the sight measures below are all secondary. Among those with room for it, 43.5% achieved a 2-step reduction in vitreous haze; mean visual acuity improved 8.22 letters and mean central macular thickness fell 83.88 micrometers. Read the design before the numbers: the trial compared two doses of tocilizumab against each other, with no placebo or active control arm, so it shows the drug is tolerated and that treated eyes improved, not that it beats an alternative.
Contraindications
ACTEMRA is contraindicated in patients with known hypersensitivity to ACTEMRA.
80 mg/4 mL, 200 mg/10 mL, 400 mg/20 mL single-dose vials (20 mg/mL); 162 mg/0.9 mL prefilled syringe or ACTPen autoinjector
Tocilizumab binds to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R), and has been shown to inhibit IL-6-mediated signaling through these receptors. IL-6 is a pleiotropic pro-inflammatory cytokine produced by a variety of cell types including T- and B-cells, lymphocytes, monocytes and fibroblasts. IL-6 has been shown to be involved in diverse physiological processes such as T-cell activation, induction of immunoglobulin secretion, initiation of hepatic acute phase protein synthesis, and stimulation of hematopoietic precursor cell proliferation and differentiation.
Warnings & Precautions
- Serious Infections: Patients treated with ACTEMRA are at increased risk for developing serious infections that may lead to hospitalization or death, including invasive fungal infections and bacterial, viral and other infections due to opportunistic pathogens. Do not administer ACTEMRA during an active infection, including localized infections. If a serious infection develops, interrupt ACTEMRA until the infection is controlled. Closely monitor for signs and symptoms of infection during and after treatment.
- Viral Reactivation: Viral reactivation has been reported with immunosuppressive biologic therapies and cases of herpes zoster exacerbation were observed in clinical studies with ACTEMRA.
- Tuberculosis: Patients, except those with COVID-19, should be tested for latent tuberculosis before ACTEMRA use and during therapy. Treatment for latent infection should be initiated prior to ACTEMRA use. Monitor all patients for active TB during treatment, even if the initial latent TB test is negative.
- Gastrointestinal Perforations: Events of gastrointestinal perforation have been reported in clinical trials, primarily as complications of diverticulitis. Use ACTEMRA with caution in patients who may be at increased risk for gastrointestinal perforation. Promptly evaluate patients presenting with fever, new onset abdominal symptoms, and a change in bowel habits.
- Hepatotoxicity: Monitor patients for signs and symptoms of hepatic injury. Modify or discontinue ACTEMRA if abnormal liver tests persist or worsen or if clinical signs and symptoms of liver disease develop. Some serious cases have resulted in liver transplant or death. In RA, GCA and SSc-ILD, obtain a liver test panel before initiating ACTEMRA, every 4 to 8 weeks for the first 6 months and every 3 months thereafter. Discontinue ACTEMRA if ALT or AST rises above 5× ULN.
- Elevated Liver Enzymes: It is not recommended to initiate ACTEMRA treatment in RA, GCA or SSc-ILD patients with elevated transaminases ALT or AST greater than 1.5× ULN, or in COVID-19 patients with elevated ALT or AST above 10 × ULN. In COVID-19 patients, monitor ALT and AST during treatment.
- Neutropenia: Treatment with ACTEMRA was associated with a higher incidence of neutropenia. It is not recommended to initiate ACTEMRA in RA, GCA and SSc-ILD patients with an ANC less than 2000 per mm 3, or in COVID-19 patients with an ANC less than 1000 per mm 3. In patients who develop an ANC less than 500 per mm 3, treatment is not recommended. In RA, GCA and SSc-ILD, monitor neutrophils 4 to 8 weeks after start of therapy and every 3 months thereafter.
- Thrombocytopenia: Treatment with ACTEMRA was associated with a reduction in platelet counts. It is not recommended to initiate ACTEMRA in RA, GCA and SSc-ILD patients with a platelet count below 100,000 per mm 3. In patients who develop a platelet count less than 50,000 per mm 3, or in COVID-19 patients with a platelet count less than 50,000 per mm 3, treatment is not recommended. In RA, GCA and SSc-ILD, monitor platelets 4 to 8 weeks after start of therapy and every 3 months thereafter.
- Lipid Abnormalities: Treatment with ACTEMRA was associated with increases in lipid parameters such as total cholesterol, triglycerides, LDL cholesterol, and/or HDL cholesterol. Assess lipid parameters approximately 4 to 8 weeks following initiation of ACTEMRA therapy, then manage patients according to clinical guidelines for the management of hyperlipidemia.
- Changes in Laboratory Parameters: A similar pattern of liver enzyme elevation, low neutrophil count, low platelet count and lipid elevations is noted with ACTEMRA treatment in the PJIA and SJIA populations. Monitor neutrophils, platelets, ALT and AST at the time of the second administration and thereafter every 4 to 8 weeks for PJIA and every 2 to 4 weeks for SJIA. In COVID-19 patients, neutrophils and platelets should be monitored.
- Immunosuppression: The impact of treatment with ACTEMRA on the development of malignancies is not known but malignancies were observed in clinical studies. Treatment with immunosuppressants may result in an increased risk of malignancies.
- Hypersensitivity Reactions, Including Anaphylaxis: Hypersensitivity reactions, including anaphylaxis and death, have been reported, including as early as the first infusion and in patients who received premedication. Serious cutaneous reactions, including Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), have been reported in patients with autoinflammatory conditions. If a hypersensitivity reaction occurs, immediately discontinue ACTEMRA, treat promptly and monitor until signs and symptoms resolve.
- Demyelinating Disorders: Multiple sclerosis and chronic inflammatory demyelinating polyneuropathy were reported rarely in RA clinical studies. Monitor patients for signs and symptoms potentially indicative of demyelinating disorders, and exercise caution in patients with preexisting or recent onset demyelinating disorders.
- Active Hepatic Disease and Hepatic Impairment: Treatment with ACTEMRA is not recommended in patients with active hepatic disease or hepatic impairment.
- Vaccinations: Avoid use of live vaccines concurrently with ACTEMRA as clinical safety has not been established. It is recommended that all patients, particularly pediatric or elderly patients, if possible, be brought up to date with all immunizations prior to initiating ACTEMRA therapy.
Common Side Effects
The most common serious adverse reactions were serious infections. The most common adverse reactions (incidence of at least 5%) were upper respiratory tract infections, nasopharyngitis, headache, hypertension, increased ALT and injection site reactions.
Pregnancy: The available data with ACTEMRA from a pregnancy exposure registry, retrospective cohort study, pharmacovigilance, and published literature are insufficient to draw conclusions about a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. In animal reproduction studies, intravenous administration of tocilizumab to Cynomolgus monkeys during organogenesis caused abortion/embryo-fetal death at doses 1.25 times and higher than the maximum recommended human dose. Based on the animal data, there may be a potential risk to the fetus. Monoclonal antibodies, such as tocilizumab, are actively transported across the placenta during the third trimester of pregnancy and may affect immune response in the in utero exposed infant.
Lactation: No information is available on the presence of tocilizumab in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production. Maternal immunoglobulin G (IgG) is present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for ACTEMRA and the potential adverse effects on the breastfed child.
ACTEMRA by intravenous use is indicated for the treatment of pediatric patients 2 years of age and older with active systemic juvenile idiopathic arthritis, active polyarticular juvenile idiopathic arthritis, severe or life-threatening CAR T cell-induced cytokine release syndrome (CRS), or hospitalized COVID-19 in patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). ACTEMRA by subcutaneous use is indicated for pediatric patients 2 years of age and older with active PJIA or active SJIA. The safety and effectiveness in pediatric patients below the age of 2 have not been established in PJIA, SJIA, CRS or COVID-19.